Food and Drug Administration

Transmissible Spongiform Encephalopathy Advisory Committee

February 20, 2003


Monitoring the Blood Spply - What Do We Really Need to Know?, Dr. Alan Williams, PhD, FDA (HTM) (PPT)

Use of Sentinel Sites to Monitor the United States Blood Supply, Dr. McMurty, FDA (HTM) (PPT)

Impact of vCJD Travel Deferrals on the Blood Supply, Dr. Celso Bianco, MD, America's Blood Ctrs. (PDF)

American Red Cross: Evolution of vCJD Donor Deferral Criteria and Blood Supply, Dr. Peter Page, MD, Biomedical Hdqtrs (HTM) (PPT)

Statement Presented by New York Blood Center (HTM) (PPT)

Statement Presentation by KayR. Gregory, MS MT(ASCP)SBB, American Association of Blood Banks (HTM) (PDF) (Word)

Update on Bovine Spongiform Encephalopathy, Dr. David Asher, MD, FDA (HTM) (PPT)

Consideration of Labeling Claims for TSE Agent Clearance in Plasma Derivatives, Dr. Dorothy Scott, MD, FDA (HTM) (PPT)

Evaluation of Viral Clearance Studies, Dr. Mahmood Farshid, PhD, FDA (HTM) (PPT)

TSE Agent Clearance Issues, Dr. Dorothy Scott, MD, FDA (HTM) (PPT)

Risk Analysis for TSE and Plasma Derivatives, Dr. Steven Anderson, PhD, MPP, FDA (HTM) (PPT)

TSE & PDMP @EMEA - What's Next? (HTM) (PPT)

Removal of Prions by Plasma Fractionation Processes, Dr. Henry Baron, MD, Aventis Behring (HTM) (PPT)

Open Public Hearing

Email from Terry Singeltary, Sr. to William Freas Regarding vCJD (HTM) (PDF) (Word)